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Abstract 22 
Ureaplasma species are the microorganisms most frequently associated with adverse pregnancy 23 
outcomes. The multiple banded antigen (MBA), a surface-exposed lipoprotein, is a key virulence 24 
factor of ureaplasmas. The MBA demonstrates size variation, which we have shown previously 25 
to be correlated with the severity of chorioamnion inflammation. We aimed to investigate U. 26 
parvum serovar 3 pathogenesis in vivo, using a sheep model, by investigating: MBA variation 27 
after long term (chronic) and short term (acute) durations of in utero ureaplasma infections, and 28 
the severity of chorioamnionitis and inflammation in other fetal tissues. Inocula of 2x10
7 
colony-29 
forming-units (CFU) of U. parvum serovar 3 (Up) or media controls (C) were injected intra-30 
amniotically into pregnant ewes at one of three time points: day 55 (69d Up, n=8; C69, n=4); day 31 
117 (7d Up, n=8; C7, n=2); and day 121 (3d Up, n=8; C3, n=2) of gestation (term=145-150d). At 32 
day 124, preterm fetuses were delivered surgically. Samples of chorioamnion, fetal lung, and 33 
umbilical cord were: (i) snap frozen for subsequent ureaplasma culture, and (ii) fixed, embedded, 34 
sectioned and stained by haematoxylin and eosin stain for histological analysis. Selected fetal 35 
lung clinical ureaplasma isolates were cloned and filtered to obtain cultures from a single CFU. 36 
Passage 1 and clone 2 ureaplasma cultures were tested by western blot to demonstrate MBA 37 
variation. In acute durations of ureaplasma infection no MBA variants (3d Up) or very few MBA 38 
variants (7d Up) were present when compared to the original inoculum. However, numerous 39 
MBA size variants were generated in vivo (alike within contiguous tissues, amniotic fluid and 40 
fetal lung, but different variants were present within chorioamnion), during chronic, 69d 41 
exposure to ureaplasma infection. For the first time we have shown that the degree of ureaplasma 42 
MBA variation in vivo increased with the duration of gestation.  43 
 44 
Introduction 45 
The Ureaplasma species, bacteria from the class Mollicutes, are the most prevalent, potentially 46 
pathogenic bacteria isolated from the urogenital tract of both men and women (40-80%) [1] and 47 
are the microorganisms most frequently associated with preterm birth [2,3,4]. The ureaplasmas 48 
are among the smallest and simplest self‐replicating prokaryotes, they do not possess a cell wall 49 
and are surrounded only by a plasma membrane [5]. Ureaplasmas have a small genome, between 50 
750 kb and 1.2 M/bp in size. They have reduced biosynthetic capabilities and are therefore 51 
dependent on an animal host for survival [6,7,8].  52 
The two species of ureaplasmas known to colonize humans are U. urealyticum (serovars 2, 4, 5, 53 
7‐13) and U. parvum (serovars 1, 3, 6 and 14). Of these, U. parvum is the most common species 54 
isolated from the genital tracts of men and women [1,9,10]. Ureaplasma colonization of the 55 
female upper genital tract in pregnancy is associated with preterm labor, preterm birth, perinatal 56 
morbidity and mortality, premature rupture of membranes [8,11,12] and is a major cause of 57 
histological chorioamnionitis [1,13,14]. Ureaplasma infections are often clinically asymptomatic 58 
and the incidence is higher in women who deliver preterm [3]. Intrauterine inflammation and 59 
ureaplasma colonization induce fetal lung maturation prematurely, predisposing the infant to the 60 
future likelihood of chronic lung disease (CLD) [15]. Isolation of ureaplasmas from endotracheal 61 
secretions of newborns [16] shows that infection of the fetus can occur in utero or alternatively 62 
be acquired by vertical transmission at birth [17]. 63 
Ureaplasma infection in animal models has been associated previously with dramatic variation in 64 
the histological inflammation of infected tissues [18]. Variable inflammation may be due to 65 
different or inconsistent interactions between the ureaplasmas and the host [15,18,19]. 66 
Previously, Ureaplasma spp. were investigated using a sheep model of long term (chronic) in 67 
utero U. parvum infection. This study demonstrated that variation of the surface‐exposed 68 
ureaplasma multiple banded antigen (MBA) of serovar 6 correlated with the extent of 69 
chorioamnion inflammation [18]. The severity of chorioamnionitis correlated inversely with the 70 
number of MBA / multiple banded antigen gene (mba) size variants that existed within infected 71 
amniotic fluid (AF), suggesting that variation of the MBA/mba was associated with ureaplasmal 72 
pathogenicity [18,20]. However, the relationship between the number of MBA antigenic variants 73 
and the severity of inflammation within infected chorioamnion and other infected tissues has not 74 
been investigated for U. parvum serovar 3, or during an acute duration of infection. 75 
The 5' region of the mba encodes a conserved N‐terminal anchor of the lipoprotein whereas the 3' 76 
region of the mba encodes the C‐terminal domain, consisting of multiple tandem repeat units, 77 
which are surface‐exposed. The C‐terminal domain is antigenic and elicits an antibody host 78 
response during ureaplasma infection [21,22]. Additions or deletions in the number of repeat 79 
units in the downstream region of the mba is associated with antigenic variation [21].  80 
Our research group has utilised an ovine model to investigate the response of the fetus to a 81 
number of in utero challenges, including intra-uterine infection. The perinatal sheep model offers 82 
several advantages: the size of the fetus and fetal tissues are very similar to that of human fetuses 83 
and therefore the consequences of in vivo infection can be compared when investigating the 84 
effects on tissues. Furthermore, sheep do not deliver before 125d after intra-amniotic inoculation 85 
with ureaplasmas [23], thus providing an important control when investigating infection of 86 
different durational periods. For this study, U. parvum serovar 3, the most common serovar 87 
isolated from both males and females [1], was injected into pregnant ewes at one of three time 88 
points throughout the gestational period. We hypothesised that exposure of fetal tissues to either 89 
chronic or acute durations of ureaplasma infection would result in marked differences in MBA 90 
size variation between treatment groups and that this would correlate with varied inflammatory 91 
and histological responses within the fetal tissues. 92 
 93 
Material and Methods 94 
Out bred pregnant sheep (n=32) were assigned to six experimental groups for this project. This 95 
study was carried out in accordance with the National Health and Medical Research Council 96 
‘Australian code of practice for the care and use of animals for scientific purposes’ and approved 97 
by The University of Western Australia Animal Ethics Committee (Approval No. RA3/100/619). 98 
U. parvum serovar 3, strain 442S (isolated originally from semen of infertile men attending the 99 
Wesley IVF Service [9]) was injected into the amniotic sac of ewes bearing singleton 100 
pregnancies. Using ultrasound guidance, AF was aspirated prior to inoculation and tested to 101 
confirm it was AF (and not allantoic fluid). Ureaplasma inocula of 2x10
7
 CFU were injected 102 
intra‐amniotically at: day 55 of gestation (n=8, term=145-150 days gestation); day 117 (n=8); 103 
and day 121 (n=8). All fetuses were delivered surgically at 124 days (preterm). Controls groups 104 
included sheep inoculated with 10B media [24] at day 55 of gestation (n=4); day 117 (n=2) and 105 
day 121 (n=2) of gestation.  106 
Delivery and tissue sampling  107 
Ewes were anaesthetised, the fetuses were delivered surgically and samples of AF, 108 
chorioamnion, fetal lung (FL), umbilical cord (CORD) and cerebrospinal fluid (CSF) were 109 
collected aseptically for subsequent culture [18,25]. The pH of AF and FL was measured. The 110 
deflation limb of a pressure‐volume curve was performed to measure lung compliance up to a 111 
pressure of 40 cm H2O [2,23]. Lung samples of the right upper lobe and right middle lobe were 112 
also collected aseptically for subsequent histological analysis and culture [2]. Specimens were 113 
either snap frozen in liquid nitrogen and stored (‐80°C) or fixed in 4% formalin [2,23].  114 
Culturing and Quantification 115 
To detect ureaplasmas within AF, chorioamnion, CORD and FL, samples were cultured. Thawed 116 
chorioamnion, CORD and FL (0.1 grams) were homogenized and cultured as previously 117 
described [2,18] in 10B broth and on A8 agar [26] to determine the number of CFU of 118 
ureaplasmas per gram of tissue or per mL of fluid. Broths then were incubated at 37°C, 119 
aerobically for 24‐48 hours. Ureaplasma spp. growth was detected by an alkaline shift in the 120 
broth media due to the production of ammonia [26]. Agar plates then were incubated at 37°C, 121 
under 5% CO2 for 48‐72 hours, and ureaplasma colonies were counted using a stereomicroscope 122 
(Leica Microsystems, North Ryde, NSW).  123 
 124 
Histology 125 
The formalin‐fixed chorioamnion, CORD and FL samples were paraffin embedded, and 5‐10 μm 126 
sections cut. The sections were heated overnight at 60°C and then stained with haematoxylin and 127 
eosin (H & E). The stained tissues were examined blindly and the number of white blood cells 128 
(WBC): monocytes, neutrophils; and lymphocytes present in 20 microscopic fields per slide at x 129 
1000 magnification were counted. The H & E tissue sections were visually examined by a 130 
perinatal pathologist, and graded according to the diagnostic criteria outlined by Redline et al. 131 
[27]. 132 
 133 
Cloning and Filtration 134 
Ureaplasmas isolated from selected FL samples from animals chronically colonized 135 
intra‐amniotically with ureaplasmas were cloned and filtered twice, as previously described 136 
[18,28], to obtain ureaplasma cultures originating from a single CFU. The FL tissues were 137 
selected from fetuses associated with chorioamnionitis of a mild grade, a severe grade and a third 138 
in which scar formation occurred within the chorioamnion. The original ureaplasma inoculum 139 
(442S) was also cloned and filtered as a control.  140 
 141 
DNA Extraction 142 
Ureaplasma DNA was extracted and purified from AF and tissue homogenates, of chorioamnion, 143 
CORD and FL collected from all animals using the QIAamp DNA Mini Kit (QIAGEN Ltd, 144 
Crawley, UK) according to the manufacturer's tissue protocol.  145 
DNA was also obtained from each passage 1 (P1) culture for all tissues (AF, chorioamnion, 146 
CORD and FL) and from clone 2 (C2) FL ureaplasma cultures using previously described 147 
methods [29]. Briefly, 500 μL of cultures were centrifuged, the supernatants discarded, and the 148 
pellets each resuspended in 125 μL Solution A (10 mM Tris HCl pH 8.5, 100 mM KCl, 2.5 mM 149 
MgCl2), 125 μL Solution B (10 mM Tris HCl pH 8.5, 2.5 mM MgCl2, 1% v/v Tween 20, 1% 150 
v/v Triton X) and proteinase K (120 μg/mL). Specimens then were incubated at 60°C for 1 hour, 151 
then 94°C for 10 minutes, and then stored at ‐20°C.  152 
 153 
Polymerase Chain Reactions (PCR) 154 
PCR primers were designed using the U. parvum serovar 3 reference serovar genome sequences; 155 
strain ATCC700970 [8], and the more recent ATCC27815 strain. The PCR primers, UMS3UF 156 
and UMS3UR (F
5'
TTACCAAATCTTAGTGTTC
3'
, R
5'
CTGGTTGTGTAGTTTCAAAG
3'
) 157 
amplified the conserved upstream region of the mba. Cycling involved an initial denaturing 158 
period at 95°C for 15 minutes, followed by 35 cycles involving: denaturation at 95°C for 1 159 
minute, primer annealing at 54°C for 1 minute, extension at 72°C for 1 minute, and a final 160 
extension step at 72°C for 10 minutes. The downstream repeat region of the mba was amplified 161 
with designed primers UMS3DF (F
5'
CTTTGAAACTACACAACCAG
3'
) and UMS3DR 162 
(R
5'
TTCAGGTTTAAAAAATGGGC
3'
). For this reaction, cycling conditions involved an initial 163 
denaturing period at 95°C for 10 minutes, followed by 40 cycles of 95°C for 45 seconds, 164 
52‐54°C for 75 seconds, and 72°C for 2 minutes and a final extension step at 72°C for 15 165 
minutes.  166 
The PCR assay was performed in a total volume of 50 µL with final concentrations of 0.1 mM of 167 
dNTPs (Invitrogen, Mt Waverley, VIC), 1 x PCR buffer (Tris HCL, KCL, (NH4)2SO4, pH 8.7; 168 
Invitrogen), 45 mM MgCl2 (Invitrogen), 0.5 µM of each primer (Sigma-Proligo, Castle Hill, 169 
NSW), 1U Platinum Taq (Invitrogen), 8 µL of template DNA, and 32 µL of UltraPure 170 
DNase/RNase-Free distilled water (Invitrogen). Positive controls for all PCR assays included the 171 
initial U. parvum serovar 3 inoculum (442S) and the U. parvum serovar 3 reference serovar 172 
corresponding to strain ATCC27815 (Courtesy of H. Watson, University of Alabama, 173 
Birmingham). Master-mix only and dH2O negative controls were also included in each PCR 174 
assay. PCR amplicons were analysed by electrophoresis using a 2% agarose tris borate EDTA 175 
(TBE) gel at 100 volts for 60 minutes and visualised by ethidium bromide staining.  176 
 177 
SDS PAGE and Western Blot 178 
Ureaplasma P1 cultures from AF, chorioamnion, CORD and FL tissue, and C2 FL cultures were 179 
analysed by western blot analysis as previously described [18]. For this protocol the membranes 180 
were incubated with primary antibody diluted 1/10000 (polyclonal rabbit serum raised against U. 181 
parvum serovar 3, courtesy of Emeritus Dr Patricia Quinn, Toronto, Ontario). The positive 182 
controls for the western blots were cultures of the U. parvum serovar 3 initial inoculum (442S) 183 
and U. parvum serovar 3 reference serovar [8,30]. A 10B media negative control was included to 184 
demonstrate any cross‐reactivity of the antiserum with components of the 10B broth media.  185 
 186 
Statistical Analysis 187 
Data are presented as mean ± standard error of the mean (SEM). One‐way analysis of variance 188 
(ANOVA) was used to analyse the numbers of ureaplasma in AF (CFU/mL) and chorioamnion, 189 
CORD, and FL tissues (CFU/g) and to examine differences between chronic and acute 190 
ureaplasma treatment groups. Two‐way ANOVA was used to analyse differences between 191 
treatment cohorts, inflammatory cell counts and inflammatory cell type. Univariate random 192 
effect ANOVA using the general linear model was used to analyse FL pressure-volume curves 193 
(PV curves) for differences between treatment groups, ureaplasma infection duration and 194 
pressure, p values of ≤ 0.05 were considered statistically significant.  195 
 196 
Results 197 
Fetus Delivery  198 
Pregnancy losses included two fetuses from ewes injected intra‐amniotically with ureaplasmas at 199 
55 days gestation and two fetuses from ewes that were injected at 117 days gestation. There was 200 
also one pregnancy loss from a control animal injected with media at 121 days of gestation. A 201 
final count of 27 singleton fetuses were sampled across the 6 experimental groups.  202 
 203 
Culturing and Quantification  204 
Ureaplasmas were cultured from 100% of AF, 90% of FL, 65% of chorioamnion and 35% of 205 
CORD tissue samples from animals that were injected intra‐amniotically with ureaplasmas. No 206 
ureaplasmas were detected in the tissues from animals injected with the media control. A total of 207 
80 passage 1 (P1) ureaplasma cultures were obtained from these tissues for further analysis. 208 
Ureaplasmas were not detected in any CSF specimens by culture or PCR assay. The mean 209 
ureaplasma titre (CFU/mL) was higher (> 10
6
 CFU per mL) in the amniotic fluid of animals 210 
across all treatment groups (p < 0.007) when compared to ureaplasma titres in the other tissues 211 
collected from the same animal. Differences were not statistically significant for the other tissues 212 
and the different treatment groups.  213 
 214 
pH analysis of amniotic fluid (AF) and fetal lung (FL) fluid  215 
The mean AF pH was higher in animals exposed to ureaplasma infection from 55 ‐ 124 days (69 216 
days) of gestation (pH = 7.36 ± 0.1) compared to the pH of AF from control animals (pH = 6.9 ± 217 
0.1) (p = 0.03) and AF of animals exposed to acute ureaplasma infection (3 days, pH = 6.9 ± 0.1, 218 
p = 0.02). No AF pH differences were observed between any of the acute or control treatment 219 
groups (Figure 1).  220 
 221 
The FL fluid pH was also higher in animals exposed to chronic ureaplasma infection (pH = 6.5 ± 222 
0.1) than for animals exposed to ureaplasmas for 7 days (pH = 6.3 ± 0.1), 3 days (pH = 6.3 ± 0.1) 223 
or control animals (pH = 6.3 ± 0.1) (p = 0.0058). There were no significant FL fluid pH 224 
differences between animals exposed to ureaplasmas for 7 days or 3 days and control animals.  225 
 226 
Lung Pressure-Volume Curve  227 
Animals exposed to chronic (69d) ureaplasma infection (p = 0.0365) showed greater mean lung 228 
compliance in comparison to the media control group; and also when compared to the 3d acute 229 
(p = 0.165) and the 7d acute treatment groups (p = 0.49) (Figure 2).  230 
 231 
Histology 232 
The number of inflammatory cells (neutrophils, monocytes, and lymphocytes) in the 233 
chorioamnion tissues from animals injected with ureaplasmas was compared to the cell numbers 234 
in animals inoculated with media control. Surprisingly, there were no differences in 235 
inflammatory cell numbers within the chorioamnion of animals injected with ureaplasmas and 236 
the chorioamnion tissue from the media control groups (p = 0.278). Whilst neutrophils counts 237 
were higher than the other inflammatory cell types observed in the tissue (i.e. monocytes and 238 
lymphocytes), this difference was not significant (p = 0.068). 239 
The amniotic fluid and fetal lung pH values were also correlated with the inflammatory cell 240 
counts within the chorioamnion and fetal lung H & E tissue sections. However, elevated pH 241 
within these body fluids was not associated with elevated inflammatory cell counts (R
2 
< 0.04).  242 
Variability in the severity of inflammation was observed in tissues of animals exposed 243 
chronically to ureaplasmas. The appearance of chorioamnion tissues exposed to chronic (69d) 244 
ureaplasma infection ranged from severe inflammation with thickened epithelial membranes, 245 
irregular shaped epithelial cells and infiltration of WBCs throughout the collective tissues layers 246 
(Figure 3A- arrowed), to mild inflammation with thickening of epithelium cells (Figure 3B); or 247 
to chorioamnion with fibrous scar tissue and degraded architecture (Figure 3C). In the 248 
chorioamnion, from control animals no thickening of the epithelium and only mild inflammatory 249 
changes were observed (Figure 3D). The FL tissue appearance also ranged from mild 250 
inflammation (Figure 3B), similar in appearance to the control tissue (Figure 3D); to severe 251 
inflammation with an influx of WBCs into the tissue (Figure 3A); to a high degree of fibrosis 252 
and scarring (Figure 3C). CORD tissue exposed to chronic (69d) ureaplasma infection also 253 
demonstrated mild inflammation with low numbers of WBCs present (Figure 3B); to severe 254 
inflammation with high WBC counts in the tissues (Figure 3A). CORD tissue also demonstrated 255 
fibrosis and scarring (Figure 3C). The variable degrees of inflammation observed in the FL and 256 
CORD tissues correspond consistently with the severity of histological chorioamnionitis 257 
observed in the chorioamnion tissues from the same animals. 258 
 259 
Summary of pathology: 260 
Pathology results using the Redline classifications [27] summarised in Table 1, demonstrated 261 
that the severity of inflammation of the maternal and fetal chorioamnion membranes  increased 262 
with the duration of ureaplasma colonization. Interestingly acute chorioamnionitis, a stage 2 263 
maternal response (Table 1) was present in all of the control animal tissues as well as the tissues 264 
infected with ureaplasmas for 3d, 7d, or 69d. This maternal response may indicate an 265 
inflammatory response to components within the 10B media. However, the increased duration of 266 
exposure to intra-amniotic ureaplasmas was associated with an influx of macrophages and 267 
neutrophils within the maternal membranes of the chorioamnion when compared to the response 268 
within the control tissues (Maternal response Stage 2/Grade 1(b) – Table 1). 269 
By contrast, only one (14%) of the control tissues (a 69d control) demonstrated a fetal membrane 270 
inflammatory response within the chorioamnion compared to 25% (3d), 66.5% (7d) and 83.5% 271 
(69d) of the tissues exposed to ureaplasmas (Fetal response Table 1).  272 
 273 
Analysis of Passage 1 (P1) Cultures - Western blot Analysis  274 
Western blot analysis of P1 ureaplasma cultures obtained from FL, AF and chorioamnion tissues 275 
(of animals exposed to acute 3d intra‐amniotic ureaplasma infection) demonstrated no size 276 
variation of the MBA in comparison to the 442S original U. parvum serovar 3 inoculum (50 277 
kDa) (Figure 4 A1, B1, C1). After 7 days in vivo P1 ureaplasmas demonstrated minor size 278 
variation of the MBA in isolates from the FL/chorioamnion (Figure 4 A2, C2). By contrast, 279 
dramatic size variation of the MBA antigen was observed in P1 ureaplasmas from the FL, AF 280 
and chorioamnion of animals chronically infected/colonized with ureaplasmas (from day 55 of 281 
gestation) (Figure 4 A3, B3, C3). 282 
A comparison of the MBA variation within AF and FL tissues collected from the same animals 283 
(which were inoculated at 55 days of gestation) demonstrated common MBA variants within 284 
these tissues: sample A76 and L76 (Figure 4 A3, B3) both showed two comparable MBA size 285 
variants (60 kDa and 55 kDa); sample A60 and L60 (Figure 4 A3, B3) both showed three 286 
comparable size variants (75 kDa, 60 kDa and 50 kDa); samples A28 and L28 (Figure 4 A3, B3) 287 
both showed two comparable size variants (75 kDa and 50 kDa); and samples A30 and L30 288 
(Figure 4 A3, B3) both showed one comparable size variant (100 kDa) (NB ‐ lower bands in A30 289 
are due to overflow from A60). However, there were exceptions: for L77 there was no band but a 290 
band was present in A77 (Figure 4 A3, B3); and A29 demonstrated two size variants (150 kDa, 291 
90 kDa) but L29 showed only one variant (150 kDa) (Figure 4 A3, B3). However, the pattern of 292 
variation observed in the AF and FL tissues from the same animal was not consistent with the 293 
variation observed in the corresponding chorioamnion (Figure 4 C3). Unfortunately, no 294 
ureaplasmas were cultured from CORD specimens that were exposed to chronic ureaplasma 295 
infection.  296 
PCR assays were performed on each of the P1 and clone 2 clinical ureaplasma isolates. PCR 297 
assays of the downstream region of the mba gene demonstrated size variation of the mba (results 298 
not shown) and the mba size variants detected by PCR correlated directly with the western blot 299 
MBA size variants.   300 
 301 
Fetal lung Clone 2 Analysis - Western blot Analysis (Fetal lung C2)  302 
Cloning and filtering was performed on selected FL tissues (L60, L30 and L29), those 303 
chronically exposed to ureaplasmas for 69 days in vivo, to obtain cultures from a single CFU. 304 
Seven C2 isolates for each FL tissue then were tested by western blot, and mba PCR (data not 305 
shown). Each C2 ureaplasma isolate demonstrated only a single MBA variant (Figure 5A, B and 306 
C).   307 
The C2 isolates from the severely inflamed FL tissue, L29 (Figure 5A), demonstrated 3 size 308 
variants (150 kDa, 140 kDa, 50 kDa) and these variants also demonstrated the greatest size 309 
variation of the MBA when compared to the initial inoculum (442S). The C2 isolates from the 310 
mildly inflamed FL tissue, L30 (Figure 5B), demonstrated 2 size variants (105 kDa and 75 kDa). 311 
By contrast, clones isolated from scarred FL tissue, L60 (Figure 5C), demonstrated only one 312 
MBA variant (50 kDa) by western blot analysis and this was equivalent in size to the 442S 313 
(ureaplasma inoculum) variant.  314 
 315 
Discussion 316 
This study investigated the effects of high dose (2 x 10
7
 CFU) U. parvum serovar 3 on the 317 
preterm sheep fetus after intra‐amniotic infection/colonization and different durations of 318 
infection. Importantly we demonstrated dramatic MBA size variants within the AF, FL and 319 
chorioamnion, that were directly associated with the duration of in vivo ureaplasma colonization. 320 
Ureaplasmas cultured from animals inoculated with ureaplasmas at day 121 (3d acute) and day 321 
117 (7d acute) showed little or no variation of the MBA. By contrast, the MBA of ureaplasmas 322 
isolated from animals inoculated with ureaplasmas at day 55 of gestation (69d chronic) showed a 323 
large degree of MBA size variation. Zheng et al. [20,21] demonstrated MBA variation among 324 
four clinical isolates (each from a single CFU) obtained from an ureaplasma culture from an 325 
infected FL specimen of a newborn infant: the clinical ureaplasmas cultured contained a mixture 326 
of mba size variants. More recently, we showed that variation of the surface exposed antigen 327 
(MBA) of ureaplasma occurred in vivo in an animal model after chronic durations of infection 328 
and that variation of the antigen correlated directly with variation of the mba gene [18]. In this 329 
current study we show for the first time that the degree of ureaplasma MBA variation in vivo 330 
increased over the duration of infection/gestation. Both this study and our previous study [18]; 331 
show that fewer MBA variants are generated in vivo by serovar 3 in contrast to serovar 6 [18]. 332 
Furthermore, whilst serovar 6 generated both larger and smaller size variants in comparison to 333 
the original inoculum used in the study (U. parvum serovar 6, 306S) [18], only larger MBA 334 
variants were generated by serovar 3 (U. parvum serovar 3, 442S, this study and [18]). Size 335 
variation of the MBA may be a mechanism that ureaplasmas utilise to evade immune pressures 336 
from the host (the innate and acquired immune responses) [18,21,25]. However, we showed 337 
recently, that size variation of the MBA did not directly contribute to the severity of 338 
inflammation and chorioamnionitis [25]. Instead, we proposed that variation of the surface 339 
exposed MBA antigen may prevent the eradication of ureaplasmas by the host immune response.   340 
After short term (acute 3d and 7d) durations of ureaplasma infection in vivo, there was 341 
insufficient time to generate the numerous MBA size variants that were observed in isolates 342 
obtained from animals exposed to chronic ureaplasma infection. Bacterial surface exposed 343 
antigen(s) often contain pathogen‐associated molecular patterns (PAMPs) that host cells and 344 
receptors, such as Toll‐like receptors (TLR), recognise [31]. Shimizu et al. [32] demonstrated 345 
that the MBA is a major virulence factor of U. parvum and is recognised by TLR1, TLR2 and 346 
TLR6, inducing an inflammatory response. The development of a specific antibody response is 347 
an important component of the host defence against many mycoplasmal diseases, including 348 
ureaplasmas [22,33]. The host immune system requires time to generate a specific immunity to 349 
foreign antigens. Previously, we demonstrated an influx in inflammatory cells (neutrophils and 350 
monocytes) within fetal bronchoalveolar lavage fluid after 3, 6 or 10 weeks of U. parvum  351 
serovar 3 intra-amniotic colonization, but not after 1 week [23]. This inflammatory cell influx is 352 
consistent with reports of the first antibodies in sheep being produced after 7‐14 days of exposure 353 
to infection [34,35]. In this current study, we observed little or/ no variation in the MBA during 354 
the early exposure of 3d/7d acute ureaplasma infection. By contrast, in the chronic 69d 355 
ureaplasma infection group, the host immune response and immunoreactivity would be well 356 
established [23,25] and in this animal cohort dramatic variation in the MBA was observed. These 357 
observations further support the hypothesis that interactions between ureaplasma organisms and 358 
the host immune response stimulate variation within the MBA [15,19,23,25]. Our study, together 359 
with these earlier findings, suggests that size variation of the MBA may be a mechanism by 360 
which ureaplasmas alter the PAMPs contained in this surface antigen and this may enable the 361 
ureaplasmas to evade the host immune system.  362 
The pattern of MBA variation observed in the current study was not always conserved between 363 
different tissues from the same animal. Ureaplasma isolates obtained from chorioamnion 364 
specimens showed variation of the MBA, which was different to the MBA variation observed in 365 
isolates from AF and FL tissues, in which identical variants were detected in the same animal. 366 
These results are not surprising as the AF and FL are contiguous in utero and therefore 367 
ureaplasmas were exposed to the same immune pressures from the host. The divergent variation 368 
of the ureaplasma MBA observed in the chorioamnion tissue demonstrates that ureaplasmas were 369 
exposed to different selective pressure in this different tissue compartment [36]. Microbes have 370 
the ability to adapt to anatomical differences (e.g. chorioamnion versus FL/AF), regulating 371 
expression patterns/virulence factors in response to different environmental cues (e.g. 372 
osmolarity, pH, oxygen, or ions) [37]. Furthermore, these expression patterns evolve/change over 373 
time [38], suggesting another reason for the differences observed in ureaplasma MBA variation.  374 
 375 
We also observed an increase in the severity of inflammation within the chorioamnion associated 376 
with an increase in the duration of exposure to intra-amniotic ureaplasmas (Table 1). However, 377 
there was also variability in the severity of inflammation within chorioamnion tissues from 378 
animals exposed to chronic ureaplasma infection (69d). Knox et al. showed that ureaplasmas 379 
have the ability to chronically colonize the AF without inducing histological chorioamnionitis in 380 
some animals [18]. In the current study, only minimal inflammation was observed in 381 
chorioamnion tissues collected from some animals, which were colonized with ureaplasmas in 382 
utero for 69 days; for example, the chorioamnion tissue (Figure 3B), showed little 383 
change/inflammation when compared to the control chorioamnion tissue (Figure 3D). By 384 
contrast, severe chorioamnionitis (Figure 3A) and inflammation with scarring (Figure 3C) was 385 
observed in other animals. Furthermore, there were large variations in the inflammatory cell 386 
counts within the chorioamnion specimens collected from animals in each treatment cohort. 387 
Higher WBC counts were detected in chorioamnion tissues chronically exposed to ureaplasmas 388 
but the variability in counts between animals in each treatment group produced large error bars 389 
and as a result there was no significant difference found. The variability in histological 390 
presentation and the inflammatory cell counts in the chorioamnion tissues chronically exposed to 391 
ureaplasmas provide further evidence that in some ureaplasma infections the host immune 392 
response is actively avoided.  393 
Previously, Knox et al. [18] demonstrated that size variation of the MBA of U. parvum serovar 6 394 
correlated directly with size variation of the downstream repeat region of the mba in the sheep 395 
model. In this study we compared MBA and downstream mba size variation of P1 and C2 396 
ureaplasmas cultured from fetal tissues and confirmed by PCR and western blot that the size 397 
variability of the MBA, the expressed lipoprotein, correlated with the size variation of the 398 
downstream repeat region of the mba gene. 399 
Our results demonstrated increased lung compliance and maturation of the fetal preterm lung as a 400 
result of chronic (69d) intra-amniotic U. parvum serovar 3 infection but not after infection of ≤ 1 401 
week. Previously, preterm fetal lung maturation was also observed in this sheep model [18] in 402 
animals infected chronically after intra‐amniotic inoculations with serovar 6 [18] or serovar 3 403 
[18,23]. This suggests that while the mechanism of MBA/mba variation may differ between 404 
ureaplasma serovars, the resulting pathological effect on the preterm fetal lung is similar. 405 
Preterm fetal lung maturation was also observed previously after intra-amniotic administration of 406 
Escherichia coli endotoxin [23,39]. These experimentally induced intra-amniotic 407 
infections/inflammations resulted in increased pulmonary surfactant within preterm lungs and 408 
improved lung function (lung compliance) in preterm lungs, which is consistent with the reduced 409 
risk of respiratory distress syndrome observed for preterm infants exposed to intra-uterine 410 
infection prior to birth [40]. 411 
The differences observed between U. parvum serotypes and their corresponding pathogenicity in 412 
vivo may be attributed to the mechanism(s) ureaplasmas utilise to vary the mba. A number of 413 
mechanisms can be employed by microbes to generate gene size variation, such as site‐specific 414 
DNA rearrangements and gene conversion mechanisms [41]. DNA size variation can occur from 415 
the expansion or contraction of the number of repeat units through the mechanism of 416 
slipped‐strand mispairing (SSM). SSM involves the misalignment of the repeat sequences 417 
between the daughter and parent strands during chromosomal replication or DNA repair. 418 
Misalignment of these strands can occur on the leader or lagging strand at the repeat region, 419 
resulting in an increase or decrease in the number of repetitive units in the newly synthesised 420 
DNA [29,41,42,43]. SSM-mediated variation demonstrates repeat instability and allows for 421 
different combinations of variants to be expressed simultaneously [41,42] as we have observed in 422 
the mba downstream repeat region of ureaplasma isolates cultured from animals exposed to 423 
chronic (69d) infection. Therefore, we propose that SSM mediated variation is the predominant 424 
mechanism utilised by ureaplasmas to alter the number of repeating units of the downstream 425 
region of the mba.  426 
Analysis of the pH of amniotic fluid and fetal lung fluid at delivery (124d) demonstrated that 427 
chronic exposure to ureaplasmas resulted in an alkaline shift. Ureaplasmas hydrolyse urea as 428 
their sole source of energy, resulting in ammonium ions as a by‐product of hydrolysis. The 429 
accumulation of ammonia after 69d of ureaplasma colonization resulted in the pH shift in the AF 430 
and the FL fluid. An alkaline environment inhibits the growth potential of ureaplasmas in vitro 431 
[44,45,46]. The pH of the environment in utero is therefore likely to be a limiting factor of 432 
ureaplasma growth. Ammonia reacts with water in tissues to form the strong alkali, ammonium 433 
hydroxide, which at high concentrations can cause chemical burns and damage the respiratory 434 
epithelium [47,48]. Chronic lung disease after exposure to ammonia has been reported in adults 435 
[49]. We showed that an elevated pH in either the amniotic fluid or fetal lung fluid did not 436 
correlate with increased inflammatory cell counts in the chorioamnion or fetal lung tissue. 437 
However, in the presence or absence of inflammation, the ammonia liberated by ureaplasmas 438 
may contribute to the chronic tissue damage and pathology observed within the chorioamnion 439 
and the fetal lung in utero. The significance of association between ureaplasmas and preterm 440 
birth highlights the need to investigate the pathogenicity of ureaplasma colonization in utero and 441 
the association with adverse pregnancy outcomes. Our study has demonstrated for the first time, 442 
that ureaplasma MBA variation occurs after 7 days of in vivo ureaplasma colonization and this 443 
supports the proposal that variation occurs in response to the host immune system particularly as 444 
different MBA variants were detected in AF and fetal lung compared to those generated within 445 
the chorioamnion. The mechanism of MBA variation may therefore be a means by which 446 
ureaplasmas evade the host immune response and may also account for the pathological 447 
differences observed in the tissues from animals in each treatment group. Alternatively, the 448 
variation of the surface exposed MBA antigen may prevent the eradication of ureaplasmas by the 449 
host immune response [25]. We have progressed understanding of the link between MBA 450 
variation in U. parvum serovar 3. Further investigations of potential mechanisms enabling 451 
ureaplasmas to elude host immune responses will contribute to the understanding of ureaplasma 452 
pathogenicity and their role in preterm birth. 453 
 454 
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Figure 1. Amniotic fluid and fetal lung fluid pH analysis 584 
AF from 69 day chronic ureaplasma exposed animals showed a higher pH when compared to 585 
control animals (*p = 0.03) and 3 day acute animals (*p = 0.02). FL fluid from 69 day chronic 586 
ureaplasma exposed animals also showed a statistically higher pH (*p = 0.0058) when compared 587 
to the pH of FL from7d and 3d acute animals and control animals. 588 
Figure 2.  Lung Pressure-Volume (PV) curve, performed on fetal lungs at time of preterm 589 
delivery  590 
Animals exposed to chronic (69d) ureaplasma infection (* p = 0.0365) showed greater lung 591 
compliance in comparison to the media control group; the 3d acute (p = 0.165) and the 7d acute 592 
(p = 0.49) treatment groups.   593 
Figure 3. H & E staining of tissues selected from three animals exposed to chronic, 69d, intra-594 
amniotic ureaplasma infection. Variable levels of inflammation were observed in chorioamnion, 595 
umbilical cord, and FL tissues. These animal tissue images were selected based on the severity of 596 
inflammation within the chorioamnion: A: severe chorioamnionitis; B: mild chorioamnionitis; C: 597 
scarring of chorioamnion; and D: Uninfected (control), minimal inflammation. The severity of 598 
inflammation observed in the FL and CORD tissues corresponded consistently with the severity 599 
of histological chorioamnionitis. 600 
Figure 4.  P1 Western blot demonstrating MBA antigenic variation 601 
Western blots comparing antigenic variation of P1 ureaplasma isolates from animals 602 
colonized/infected with U. parvum serovar 3 for 69 days (chronic infection), 7 days and 3 days 603 
(acute infection). The number of antigenic variants (single bands) within A. FL (L samples), B. 604 
AF (A samples), and C. chorioamnion (C samples) P1 cultures are compared.  605 
442S = serovar 3 initial inoculum control; 10B = 10B media negative control; M = Precision 606 
Plus Dual Colour Protein Standard (BioRad, Gladesville, NSW).  607 
Figure 5. Western blots of FL clone 2 ureaplasma isolates  608 
A: In specimen L29, 3 ureaplasma size variants (150 kDa, 140 kDa, 50 KDa) were detected in 609 
this severely inflamed lung tissue; B: Specimen L30: Mildly inflamed tissue demonstrating 2 610 
size variants (105 kDa and 75 kDa); C: L60: Scarred tissue demonstrating only 1 size variant (50 611 
kDa). 612 
442S = serovar 3 initial inoculum control; Marker = Precision Plus Dual Colour Protein Standard 613 
(BioRad, Gladesville, NSW). The numbers identify the lung tissue (L29, L30 and L60) and the 614 
C2 isolate number.  615 
 616 
 617 
618 
 619 
 620 
1  
maternal inflammatory responses as stage 1 (early; acute subchorionitis or chorionitis), stage 2 (intermediate; acute 621 
chorioamnionitis), and stage 3 (advanced; necrotizing chorioamnionitis),  Grade 1: mild-moderate; (a) with 1+ 622 
macrophages within the chorion; (b) with 2+ macrophages and  ≥ 1+  neutrophils within the chorion; Grade 2: 623 
severe 624 
2 
fetal inflammatory responses as stage 1 (early; chorionic vasculitis or umbilical phlebitis), stage 2 (intermediate; 625 
umbilical vasculitis, one or two arteries, and/or vein or umbilical panvasculitis, all vessels), and stage 3 (advanced; 626 
[subacute] necrotizing funisitis or concentric umbilical perivasculitis). Grade 0: nil; 1: mild-moderate; Grade 2: 627 
severe.   (Redline et al. 2003). 628 
Severity  
Maternal
1
 
response 
 
Duration of intra-amniotic ureaplasma 
colonization 
Stage
 
Grade
 
Control 3 Days 7 Days 69 Days 
  n animals 
3
 (%) n animals (%) n animals (%) n animals (%) 
 2 1(a) 6 (86%)
 
5 (62.5%) 3 (50%) 1 (16.5%) 
2 1(b) 1 (14%)
4 3 (37.5%) 3 (50%) 4 (67%) 
3 2    1 (16.5%) 
Severity  
Fetal response
2     
Stage
 
Grade
 
Control 3 Days 7 Days 69 Days 
0 0 6 (86%) 6 (75%) 2 (33.5%) 1 (16.5%) 
1 1 
 
1 (14%)
4
 
 
1 (12.5%) 3 (50%) 4 (67%) 
1 2 
 
1 (12.5%) 1 (16.5%) 1 (16.5%) 
Total animals 7 8 6 6 
3 
Control animals injected with media intra-amniotically: 3d (n=1), 7d (n=2) and 69d (n=4) prior to surgical delivery  629 
4 
a 69d control animal  630 
 631 
Table 1. Maternal/fetal chorioamnion tissue inflammatory responses for pregnant ewes 632 
colonized intra-amniotically with ureaplasmas for 3 days, 7 days or 69 days compared to the 633 
responses within control animal chorioamnion tissues 634 
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